Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-AML
2024-514517-35-00Phase 3Authorised
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Nov 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of glasdegib, daunorubicin, azacitidine, amsacrine, cytarabine and 10 more in acute myeloid leukemia (AML) (2 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Event-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
glasdegibdaunorubicinazacitidineamsacrinecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-514517-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514517-35-00.